Adicet Bio Inc [ACET] stock prices are down -1.97% to $0.96 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ACET shares have gain 12.53% over the last week, with a monthly amount glided 19.78%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright downgraded its rating to Neutral on September 11, 2024. On June 27, 2023, downgrade downgraded it’s rating to Mkt Perform. Guggenheim downgraded its rating to a Neutral. JP Morgan downgraded its rating to a Neutral and reduced its price target to $6 on June 01, 2023. JP Morgan started tracking with a Overweight rating for this stock on September 21, 2022, and assigned it a price target of $23. In a note dated March 31, 2022, SMBC Nikko initiated an Outperform rating and provided a target price of $28 on this stock.
The stock price of Adicet Bio Inc [ACET] has been fluctuating between $0.45 and $1.54 over the past year. Currently, Wall Street analysts expect the stock to reach $32.5 within the next 12 months. Adicet Bio Inc [NASDAQ: ACET] shares were valued at $0.96 at the most recent close of the market. An investor can expect a potential return of 3285.42% based on the average ACET price forecast.
Analyzing the ACET fundamentals
Gross Profit Margin for this corporation currently stands at -0.25% with Operating Profit Margin at -19.39%, Pretax Profit Margin comes in at -18.23%, and Net Profit Margin reading is -18.23%. To continue investigating profitability, this company’s Return on Assets is posted at -0.73, Equity is -0.68 and Total Capital is -0.86. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Adicet Bio Inc [NASDAQ:ACET]’s Current Ratio is 7.48. Further, the Quick Ratio stands at 7.48, while the Cash Ratio is 2.03.
Transactions by insiders
Recent insider trading involved ORBIMED ADVISORS LLC, 10% Owner, that happened on Oct 08 ’25 when 5.0 million shares were purchased.
